Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
NEW YORK and SAN DIEGO, May 12, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (Nasdaq:IMUC) in the United States District Court for the Central District of California on behalf of purchasers of ImmunoCellular securities from May 1, 2012 through December 11, 2013, inclusive (the “Class Period”).
Investors who have incurred losses in shares against ImmunoCellular Therapeutics, Ltd. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.
If you suffered a loss in the shares of ImmunoCellular Therapeutics, Ltd., and would like to assist with the litigation process as a lead plaintiff, you may, no later than June 30, 2017, request that the Court appoint you lead plaintiff of the proposed class.
The filed Complaint alleges that that Defendants made false and misleading statements and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote ImmunoCellular, which led the market to believe that ImmunoCellular’s clinical studies for its product candidate ICT-107 was going well.
On April 10, 2017, the Securities and Exchange Commission (SEC) announced enforcement actions against ImmunoCellular, as well as other individuals and entities, for engaging in stock promotion schemes.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774
